These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17137242)

  • 1. Formulary implications of management of pulmonary arterial hypertension: Part I--An overview of existing and new pharmacological treatment options.
    Feldman J; Berenbeim D
    Manag Care Interface; 2006 Nov; 19(11):51-60, 67. PubMed ID: 17137242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulary implications of management of pulmonary arterial Hypertension: Part II--Payer and provider perspectives on new therapeutic options.
    Feldman J; Berenbeim D
    Manag Care Interface; 2006 Dec; 19(12):20-6, 49. PubMed ID: 17274478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment algorithm for pulmonary arterial hypertension].
    Hoeper MM
    Herz; 2005 Jun; 30(4):326-31. PubMed ID: 15965810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pulmonary arterial hypertension in Health District 11: a patient-oriented drug utilization analysis].
    Ipponi A; Moriconi S; Pelagotti F; Lombardo G; Pagni M; Colombai R; Donati MG; Banfi R; Roccato E
    Recenti Prog Med; 2008 Sep; 99(9):443-50. PubMed ID: 19044253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic challenges for systemic sclerosis: facts and future targets.
    Cerinic Matucci M; Del Rosso A; Federico P; Livi R; Fiori G; Bartoli F; Blagojevic J; Tempestini A; Pignone A
    Ann N Y Acad Sci; 2007 Sep; 1110():448-54. PubMed ID: 17911460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and management of pulmonary arterial hypertension: Implications for respiratory care.
    Levine DJ
    Respir Care; 2006 Apr; 51(4):368-81. PubMed ID: 16563191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary arterial hypertension and HIV infection.
    Degano B; Sitbon O; Simonneau G
    Semin Respir Crit Care Med; 2009 Aug; 30(4):440-7. PubMed ID: 19634083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil 20 mg. Pulmonary arterial hypertension: for oral treatment, no better than bosentan.
    Prescrire Int; 2006 Dec; 15(86):221. PubMed ID: 17167928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary arterial hypertension: on the way to a manageable disease.
    Mucke HA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):957-62. PubMed ID: 18729002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
    Olsson KM; Hoeper MM
    Drug Discov Today; 2009 Mar; 14(5-6):284-90. PubMed ID: 19121410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the endothelium in pulmonary arterial hypertension.
    Haworth SG
    Vascul Pharmacol; 2006 Nov; 45(5):317-25. PubMed ID: 17005453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapies for pulmonary arterial hypertension.
    Takaoka S; Faul JL; Doyle R
    Semin Cardiothorac Vasc Anesth; 2007 Jun; 11(2):137-48. PubMed ID: 17536117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dana Point: what is new in the treatment of pulmonary hypertension?].
    Hoeper MM; Ghofrani HA; Grimminger F; Rosenkranz S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S191-5. PubMed ID: 18814094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.
    Oudiz RJ; Farber HW
    Am Heart J; 2009 Apr; 157(4):625-35. PubMed ID: 19332188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?
    Rich J; Hoeper MM
    Int J Clin Pract Suppl; 2009 Mar; (161):17-8. PubMed ID: 19178601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary vasodilators.
    Siobal MS
    Respir Care; 2007 Jul; 52(7):885-99. PubMed ID: 17594732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.